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Background. The pituitary adenylate cyclase activating polypeptide (PACAP) may aﬀect adipogenesis and adipose tissue formation
through interaction with its G-protein-coupled receptor VPAC1. Methods. We have used a monoclonal antibody (MAb 23A11)
blocking VPAC1 in mouse models of nutritionally induced obesity. Results. Administration of MAb 23A11 (25mg/kg body weight
i.p. twice weekly) to 5-week old male C57Bl/6 mice kept on a high-fat diet for 15 weeks had no signiﬁcant eﬀect on weight gain,
nor on subcutaneous (SC) or gonadal (GON) adipose tissue mass, as compared to the control MAb 1C8. However, adipocyte
hypertrophy was observed in SC adipose tissue of MAb 23A11 treated mice. In a second study, 24 weeks old obese mice were
treated for 5 weeks with MAb 23A11, without eﬀect on body weight or fat mass, as compared to treatment with MAb 1C8. In
addition,MAb23A11hadnosigniﬁcanteﬀectonglucosetoleranceorinsulinresistanceinleanorobeseC57Bl/6mice.Conclusion.
Blocking VPAC1 does not signiﬁcantly aﬀect adipose tissue formation in mouse models of diet-induced obesity, although it may
be associated with mild adipocyte hypertrophy.
1.Introduction
Obesity and its associated diseases such as noninsulin depen-
dent diabetes, atherosclerosis, and cardiovascular disease are
a main cause of mortality and morbidity. Development of
adipose tissue is a complex process in which growth factors,
cytokines, adipokines, proteases, and hormones control
extensive modiﬁcations in adipogenesis, angiogenesis, and
proteolytic remodeling of extracellular matrix [1]. Studies
with gene-deﬁcient mice have suggested a role for pituitary
adenylate cyclase-activating polypeptide (PACAP) in adipose
tissue development [2–4].
PACAP and vasoactive intestinal polypeptide (VIP) are
two closely related neuropeptides that bind to their common
G-protein-coupled receptors, VPAC1 and VPAC2, whereas
PACAP in addition binds to the speciﬁc receptor PAC1.
PACAP and VIP stimulate insulin secretion in a glucose-
dependentmannerandalsostimulateglucagonsecretion[5].
PACAP is expressed in neural regions of the hypothalamus
known to regulate appetite [6], and intracerebroventricular
injection of PACAP reduced short-term food intake in mice
[7]. The VPAC1 receptor is found in a wide variety of tissues,
including adipose tissue [8], and its expression is markedly
upregulated during diﬀerentiation of murine preadipocytes
intomatureadipocytes[9].Alsoinprimaryratadipocytesall
three PACAP/VIP receptors are expressed [10]. Because of its
integrative role in glucose and energy homeostasis, we have
evaluated whether VPAC1 may play a role in adipogensis and
adipose tissue formation. In this study, we have blocked the
PACAP/VPAC1 pathway in mice kept on high-fat diet, using
MAb 23A11 that was previously shown to inhibit VPAC1
signaling in mice [11, 12].
2.MaterialsandMethods
2.1. Diet Models. From birth on until 5 weeks of age,
male C57Bl/6 mice were kept on a standard fat diet (SFD)
(KM-04-k12, Muracon, Carﬁl, Oud-Turnhout, Belgium,
containing 13%kcal as fat with a caloric value of 10.9kJ
p e rg ) .I naﬁ r s ts t u d y ,5w e e k so l dm i c ew e r ek e p to n2 Journal of Obesity
a high-fat diet (HFD) for 15 weeks (TD88137, Harlan
Taklad, Zeist, The Netherlands, containing 42%kcal as fat
with a caloric value of 20.1kJ per g). MAb 23A11 with
isotype IgG1 (a kind gift from ThromboGenics NV, Leuven,
Belgium) or the control MAb 1C8 with matching isotype
(directed against human t-PA, not crossreacting with murine
t-PA) were injected intraperitoneally (i.p.) at a dose of
25mg/kg body weight twice weekly during the 15 weeks
experimental period (n = 1 2e a c h ) .I nas e c o n ds t u d y ,2 4
weeks old obese mice (kept on HFD) were injected i.p.
with MAb 23A11 (n = 12) or MAb 1C8 (n = 11) at
a dose of 25mg/kg body weight twice weekly during 5
weeks.
Mice were kept in microisolation cages on a 12h
day/night cycle, fed at libitum and weighed at weekly
intervals. At the end of the experiment, the mice were
killed by i.p. injection of 60mg/kg sodium pentobarbital
(Abbott Laboratories, North Chicago, IL). Blood was col-
lected from the retroorbital sinus on trisodium citrate (ﬁnal
concentration 0.01mol/L) and plasma was stored at −20◦C.
Epididymal (gonadal, GON) and inguinal (subcutaneous,
SC) fat pads were removed and weighed; the weight of other
organs was also recorded. Adipose tissue extracts and 10µm
paraﬃn sections for histology were prepared as described
[13].
Food intake was measured throughout the experimental
period, and expressed as g per mouse and per day. All animal
experiments were approved by the local ethical committee
(KU Leuven, P03112) and performed in accordance with
the NIH Guide for the Care and Use of Laboratory Animals
(1996)andtheguidingprinciplesoftheInternationalSociety
of Thrombosis and Haemostasis [14].
2.2. Assays. Adipose tissue sections were stained with
haematoxylin/eosin using a standard protocol, followed by
signal ampliﬁcation with the Tyramide Signal Ampliﬁcation
Cyanine System (Perkin Elmer, Boston, MA). The number
of adipocytes and their mean size were determined by
computer-assisted image analysis, using for each animal 3 to
5a r e a si n4d i ﬀerent sections; the data were ﬁrst averaged per
section and then per animal.
The presence of MAb 23A11 in the adipose tissues was
determined as follows: recombinant VPAC1 (GST fusion
protein) was bound to microtiter plates coated with an anti-
GST antibody, and after incubation with the samples bound
antibody was quantitated using an antimurine antibody. The
assay was calibrated with puriﬁed MAb 23A11 and data are
expressed as ng/mg adipose tissue.
Expression of VPAC1 mRNA in extracts of SC and
GON adipose tissues was monitored by quantitative RT-
PCR, as described [15], using the gene expression assay
Mm00449214 ml (Applied Biosystems, Foster City, CA).
Data are normalized to the expression of Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; gene expression assay
Mm00441818 A1; Applied Biosystems), and shown as ΔCt
values using the 7500 Fast System SDS software (Applied
Biosystems).
Table 1: Eﬀect of VPAC1 blockade on development of adipose
tissue in C57Bl/6 mice kept on high-fat diet for 15 weeks.
MAb 23A11 MAb 1C8
Body weight start (g) 16.7 ± 0.37 16.7 ± 0.47
Body weight end (g) 40.1 ± 1.2 39.8 ± 1.1
SC fat
Weight (mg) 1490 ± 68 1470 ± 51
Adipocyte size (µm2) 4220 ± 220∗ 3560 ± 150
Adipocyte density (×10−6/µm2) 250 ± 14∗ 290 ± 14
GON fat
Weight (mg) 2530 ± 180 2460 ± 77
Adipocyte size (µm2) 5250 ± 260 5880 ± 290
Adipocyte density (×10−6/µm2) 200 ± 9.8 180 ± 8.2
Data are means ± SEM of 12 experiments in each group. ∗P<. 05 versus
MAb 1C8.
Blood glucose concentrations were determined using
Glucocard strips (Menarini Diagnostics, Florence, Italy);
trigyceride, total, HDL, and LDL cholesterol levels were
evaluated using routine clinical assays. Blood cell analysis
was performed on a Cell-Dyn 3500 R (Abbott Diagnostics,
Abbott Park, IL). Insulin (Mercodia, Uppsala, Sweden) and
leptin (R&D Systems Europe, Lille, France) were measured
with commercially available ELISAs. cAMP levels in adipose
tissue extracts were measured by ELISA (Amersham cAMP
Biotrak Enzyme immunoassay system RPN225).
Glucose tolerance and insulin resistance tests were per-
formed, with a 3-4-day recovery period, in lean (on SFD)
and obese (on HFD) male C57Bl/6 mice treated with MAb
23A11 or MAb 1C8. Therefore, after an overnight fasting,
glucose (3mg/g body weight) or human insulin (0.5mU/g)
was injected into the peritoneal cavity. Blood was collected
via the tail vein for glucose measurement before and at
15–120 minutes after injection. For detailed analysis, the
areas under the curves (AUC) of glucose level versus time
were determined. The MAbs were administered by two i.p.
injections of 25mg/kg body weight each, given at 4 days and
1 day before the test.
2.3. Statistical Analysis. Data are expressed as means ±
SEM. Statistical signiﬁcance for diﬀerences between groups,
analyzed by nonparametric Mann-Whitney U-testing, was
set at P<. 05.
3. Results
Body weight gain throughout the 15 weeks HFD feeding
period was comparable for mice treated with MAb 23A11 or
MAb 1C8, resulting in comparable total body weights at the
end of the study (Table 1). Food intake was identical in both
groups (average of 3.4g/day throughout the experimental
period), compatible with a comparable feeding eﬃciency
(weight gain normalized to caloric intake). Treatment with
MAb 23A11 did not aﬀect SC or GON adipose tissue mass,
as compared to the control MAb 1C8. The weight of otherJournal of Obesity 3
Table 2: Eﬀect of VPAC1 blockade on metabolic parameters in
C57Bl/6 mice kept on high-fat diet for 15 weeks.
MAb 23A11 MAb 1C8
Glucose (mg/dL) 171 ± 12 175 ± 11
Insulin (ng/mL) 4.0 ± 0.70 3.1 ± 0.41
Leptin (ng/mL) 30 ±3.8 29 ± 2.1
Total cholesterol (mg/dL) 185 ± 18 191 ± 12
HDL cholesterol (mg/dL) 149 ± 13 160 ± 7.0
LDL cholesterol (mg/dL) 29 ± 5.0 23 ± 5.0
Triglycrides (mg/dL) 38 ± 5.0 41 ± 4.0
Data are means ± SEM of 12 determinations in each group.
organs including liver, spleen, kidney, pancreas, lung, and
heart was also comparable for mice in both groups (data not
shown). Analysis of adipocyte size and density revealed the
presence of signiﬁcantly larger adipocytes at lower density in
SC but not in GON adipose tissue of mice treated with MAb
23A11 (Table 1). Expression of VPAC1 mRNA in adipose
tissues was not aﬀected by treatment with MAb 23A11 (ΔCt
of 13.44 ± 0.21 and 13.14 ± 0.16 for MAb 23A11 and MAb
1C8 treated SC adipose tissues, with corresponding values
of 12.21 ± 0.19 and 12.51 ± 0.13 for GON adipose tissues).
cAMPlevelsinadiposetissueswerenotsigniﬁcantlydiﬀerent
for treatment with MAb 23A11 or MAb 1C8 (126 ± 9.8
versus 117 ± 7.6fmol/mg SC tissue and 81 ± 7.2 versus 105
± 12fmol/mg GON tissue).
Metabolic parameters were very similar after treatment
with both MAbs (Table 2). Glucose and insulin tolerance
tests in lean or obese mice yielded similar results for MAb
23A11 and MAb 1C8 treatment, as revealed by comparable
area under the curve of glucose levels versus time (Table 3).
In addition, fasting insulin levels measured at the start and
end of the protocols and at 30min after glucose injection in
the glucose tolerance tests were comparable for MAb 23A11
and MAb 1C8 treated lean as well as obese mice (data not
shown).
In a separate study, obese mice (body weight 45-46 g)
were treated for 5 weeks with MAb 23A11 or MAb 1C8.
MAb 23A11 was detected in adipose tissue extracts, at a
concentration of 4.0 ± 0.61ng/mg SC adipose tissue and
19 ± 1.1ng/mg GON adipose tissue. No diﬀerences were
observed between MAb 23A11 and MAb 1C8 treated groups
with respect to food intake (3.71 ± 0.09g/day versus 3.75
± 0.07g/day), body weight evolution (45 ± 1.2g versus 45
± 1.4g at the end), SC (1820 ± 100mg versus 1850 ±
110mg) or GON (2130 ± 68mg versus 2330 ± 140mg)
adipose tissue weight. As described above, the organ weights
and metabolic parameters were also comparable for mice
treated with either MAb (data not shown). Analysis of blood
cell composition, including white blood cells, neutrophils,
lymphocytes, monocytes, eosinophils, basophils, red blood
cells, hemoglobin and hematocrit, did not reveal signiﬁcant
diﬀerences between both groups (data not shown), whereas
the platelet count was somewhat higher in the MAb 23A11
treated mice (910 ± 71 k/µl versus 764 ± 52 k/µl; P = .14).
4. Discussion
All 3 PACAP receptors are expressed in human adipose
tissue [16] and in pancreatic islets [17], whereas VPAC1
is also found in a wide variety of other tissues [18]. In
the present study we have evaluated whether blocking the
VPAC1 pathway has the potential to aﬀect adipose tissue
development in mouse models of nutritionally induced
obesity. ThiswasachievedusingMAb23A11,ananti-VPAC1
antibodythatwaspreviouslyusedtostudytheroleofPACAP
and its receptor VPAC1 in megakaryocyte maturation [12].
The epitope of MAb 23A11 is located in a region within the
second and third extracellular loop (amino acids 278–373)
of VPAC1; this second loop is involved in VPAC1 ligand-
mediated cAMP response [19]. The dose of MAb 23A11
used in mice in this study (25mg/kg i.p. twice weekly) is
muchhigherthanthedoseusedtoeﬃcientlyblockVPAC1in
studies on megakaryocyte maturation (1mg/kg s.c. 3 times
per week); it is a dose commonly used to achieve a steady
state antibody concentration in mice. It was well tolerated
without apparent side eﬀects. We have conﬁrmed expression
of VPAC1 in adipose tissues, as well as the presence of MAb
23A11. Administration of MAb 23A11, however, had no
eﬀect on cAMP levels in adipose tissues, which may be due
to alternative compensatory mechanisms.
Platelet counts were moderately elevated, as observed
previously with this MAb [12]. The main limitation of this
study may be that inhibition of VPAC1 signaling by MAb
23A11 could not be directly demonstrated at the level of the
adipose tissue.
In mouse models of nutritionally induced obesity,
evaluating either ongoing adipose tissue development or
regression of established obesity, we did not ﬁnd a marked
eﬀect of MAb 23A11 on food intake, body weight, or adipose
tissue mass, nor on glucose tolerance or insulin resistance
in lean or obese mice. However, adipocyte hypertrophy was
observed in SC but not in GON adipose tissues of MAb
23A11 treated mice. Diﬀerent behaviour of SC and GON
adipose tissues is a common ﬁnding in many studies and
may be related to diﬀerences in gene expression regulation,
resulting in production of diﬀerent amounts of adipokines
[20]. We did not observe eﬀects of MAb23A11 on circulating
leptin concentrations, but it can not be excluded that
intracellular leptin levels are higher in the hypertrophic
adipocytes in SC fat.
Previous studies have reported that PACAP deﬁciency
may aﬀect food intake and/or adipose tissue development
[2–4]. Thus, Nakata et al. [2] observed reduced food intake
in PACAP-deﬁcient mice if fed a high carbohydrate diet
but not if fed a high-fat diet. Adams et al. [4], however,
did not observe eﬀects of PACAP deﬁciency using either
diet; when fed normal chow and kept at 21◦C, the PACAP
deﬁcient mice were leaner than wild-type littermates due
to decreased adiposity, and they displayed increased insulin
sensitivity. Tomimoto et al. [3] found that PACAP deﬁcient
mice showed signiﬁcant hypoinsulinemia, reduced food
intake, lower body weight, and reduced white adipose tissue
mass. The deﬁcient mice also displayed increased insulin
sensitivity in glucose and insulin tolerance tests. The main4 Journal of Obesity
Table 3: Eﬀect of VPAC1 blockade on glucose tolerance and insulin resistance in lean and obese mice.
Lean (n = 10) Obese (n = 6)
MAb 23A11 MAb 1C8 MAb 23A11 MAb 1C8
Body weight (g) 19 ± 0.36 20 ± 0.32 45 ± 1.4 44 ± 0.54
Glucose tolerance (AUC) 41,060 ± 2,260 44,125 ± 3,260 25,000 ± 5,000 30,800 ± 2,700
Insulin resistance (AUC) 9,580 ± 760 8,160 ± 650 14,800 ± 680 13,800 ± 900
F o rb o t hM A b s ,d a t aa r em e a n s± SEM of n experiments in each group. AUC: area under the curve of glucose levels versus time
diﬀerence with our study is that PACAP antigen remains
available in normal concentration in our mice, whereas
only its interaction with VPAC1 is blocked. Using a PACAP
receptor antagonist, [6–27] in genetically obese ob/ob mice
it was shown that feeding activity, body weight or basal
plasmaglucoseandinsulinlevelswerenotaﬀected.However,
the treatment induced impaired glucose tolerance, insulin
sensitivity and a glycaemic response to feeding [21]. It
is possible that this antagonist interferes with binding of
P A C A Pt oa l l3i t sr e c e p t o r s ,w h e r e a si no u ra p p r o a c ho n l y
VPAC1 is targeted. Our data obtained with MAb 23A11 thus
allow to conclude that VPAC1 is not involved in glucose
homeostasis or in regulation of insulin action, and that
it does not play a functional role in regulation of food
intake or adiposity. The mild adipocyte hypertrophy in SC
adipose tissues after 15 weeks of treatment may be related
to triglyceride accumulation, although this is not reﬂected
by the circulating plasma levels. In addition, at the high
concentration of MAb 23A11 used to saturate VPAC1 it
is unlikely that VIP can still bind to VPAC1, suggesting
that also the VIP/VPAC1 pathway does not play a major
role. This suggests that such regulatory eﬀects observed in
other studies may be due to interaction of PACAP with
VPAC2 or PAC1. This also implies that MAb 23A11, even
when used at high concentration, is speciﬁc and does not
aﬀect the VPAC2 or PAC1 pathways allowing normal energy
homeostasis, metabolism, and adipogenesis. In contrast, a
recent study using a VPAC1 agonist (Lys15, Arg16, Leu27)-
VIP(1-7)GRF(8-27)) reported inhibition of food ingestion,
prevention of the increases in body weight and white adipose
tissue mass induced by high-fat diet feeding in control mice,
as well as improved glucose tolerance [9]. This indicates that
activation of the VPAC1 receptor may have a functional role,
in contrast to blocking it with MAb 23A11.
The diﬀerences between studies may also be explained at
least in part by diﬀerent composition and timing of the diets,
genetic background of the mice used, and speciﬁcity of the
VPAC1 (ant)agonist.
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